New pill aims to slow Alzheimer's before it worsens

NCT ID NCT07579884

Not yet recruiting Disease control Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests an experimental pill called RP902 in 360 people with mild cognitive impairment caused by Alzheimer's disease. Participants will take the drug or a placebo for 48 weeks to see if it slows memory decline. The trial is conducted at about 50 sites in China and may extend for up to 96 more weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP902 tablets
What this could lead to: If successful, this could point toward a treatment to slow cognitive decline in early Alzheimer's disease.
What could go wrong: This is an early Phase 2 trial, so results may not confirm efficacy. The drug could fail to show benefit or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD COGNITIVE IMPAIRMENT (MCI)

More trials for these conditions

Other studies related to the condition(s) this trial covers.